Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Sage Therapeutic Com (SAGE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Latest Headlines for [[ item.sessionDateDisplayLong ]]
Sage Therapeutic Has Returned 23.1% Since SmarTrend Recommendation (SAGE)

SmarTrend identified an Uptrend for Sage Therapeutic (NASDAQ:SAGE) on June 7th, 2017 at $71.91. In approximately 2 months, Sage Therapeutic has returned 23.08% as of today's recent price of $88.51.

SAGE : 83.15 (-1.38%)
Today's Research Reports on Stocks to Watch: Neurocrine Biosciences and Sage Therapeutics

NEW YORK, NY / ACCESSWIRE / August 7, 2017 / Despite a wider net loss in the second quarter than compared to a year ago, shares of Neurocrine still closed up nearly 10% on Friday after reporting impressive...

NBIX : 53.83 (+0.52%)
SAGE : 83.15 (-1.38%)
Sage Therapeutic Rises 12.39% on Heavy Volume: Watch For Potential Pullback

Sage Therapeutic (NASDAQ:SAGE) traded in a range yesterday that spanned from a low of $78.61 to a high of $88.26. Yesterday, the shares gained 12.4%, which took the trading range above the 3-day high...

SAGE : 83.15 (-1.38%)
Sage Therapeutics Announces Second Quarter 2017 Financial Results and Provides Pipeline Update

--Positive scientific advice from European Medicines Agency on development of brexanolone in PPD provides regulatory path in EU

SAGE : 83.15 (-1.38%)
Investor Network: SAGE Therapeutics, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / August 3, 2017 / SAGE Therapeutics, Inc. (NASDAQ: SAGE) will be discussing their earnings results in their Q2 Earnings Call to be held on Thursday, August 3, 2017 at 4:30 PM...

SAGE : 83.15 (-1.38%)
Investor Network: SAGE Therapeutics, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / August 3, 2017 / SAGE Therapeutics, Inc. (NASDAQ: SAGE) will be discussing their earnings results in their Q2 Earnings Call to be held on Thursday, August 3, 2017 at 4:30 PM...

SAGE : 83.15 (-1.38%)
Interesting SAGE Put And Call Options For February 2018

Investors in Sage Therapeutics Inc saw new options become available this week, for the February 2018 expiration. One of the key data points that goes into the price an option buyer is willing to pay,...

SAGE : 83.15 (-1.38%)
5 Top Stocks to Own

Today I sorted Barchart's Top Stocks to Own list first by the highest Weighted Alpha, then by technical buy signals of 80% or more and lastly used the FlipChart feature to review the charts...

ENZ : 11.09 (+0.09%)
TDOC : 30.40 (+1.16%)
NVTR : 11.86 (-0.50%)
SAGE : 83.15 (-1.38%)
PI : 31.77 (-1.15%)
Noteworthy Friday Option Activity: SAGE, BV, ALGN

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Sage Therapeutics Inc , where a total of 1,576 contracts have traded so far, representing approximately...

SAGE : 83.15 (-1.38%)
Sage Therapeutics to Present at Goldman Sachs Healthcare Conference

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that...

SAGE : 83.15 (-1.38%)
Sage Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Sage Therapeutics (NASDAQ:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, announced that, on June...

SAGE : 83.15 (-1.38%)
Sage Therapeutics Receives Fast Track Designation for SAGE-217 for the Treatment of Major Depressive Disorder

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that...

SAGE : 83.15 (-1.38%)
Sage Therapeutics Announces First Quarter 2017 Financial Results and Provides Pipeline Update

--Advancing SAGE-217 into Part B open-label Phase 2 trial in Parkinson's disease based on initial activity signal

SAGE : 83.15 (-1.38%)
Investor Network: SAGE Therapeutics, Inc. to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / May 9, 2017 / SAGE Therapeutics, Inc. (NASDAQ: SAGE) will be discussing their earnings results in their Q1 Earnings Call to be held May 9, 2017 at 4:30 PM Eastern Time.

SAGE : 83.15 (-1.38%)
How These Biotech Stocks are Faring? -- Cymabay Therapeutics, Benitec Biopharma, Sage Therapeutics, and Catalyst Biosciences

On Tuesday, April 25, 2017, the NASDAQ Composite, the Dow Jones Industrial Average, and the S&P 500 edged higher at the closing bell. Eight out of nine sectors ended Tuesday's trading session in bullish...

BNTC : 2.15 (-2.27%)
CBAY : 6.38 (+2.08%)
SAGE : 83.15 (-1.38%)
CBIO : 3.45 (+0.58%)
BNIKF : 0.1020 (+0.99%)
Sage Therapeutics to Report First Quarter 2017 Financial Results on Tuesday, May 9, 2017

Sage Therapeutics (NASDAQ: SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that...

SAGE : 83.15 (-1.38%)
Sage Therapeutics Appoints Michael Cloonan as Chief Business Officer and Expands Executive Team

Sage Therapeutics (NASDAQ:SAGE), a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced the appointment...

SAGE : 83.15 (-1.38%)
5 Drug Stocks for Your Portfolio this World Health Day

With "Depression: let's talk" being this year's World Health Day campaign slogan, here's a look at 5 companies developing treatments for various types of depression.

JNJ : 133.35 (-0.61%)
AGN : 227.24 (-0.33%)
SAGE : 83.15 (-1.38%)
ALKS : 51.31 (-0.48%)
VTGN : 1.76 (-4.35%)
First Week of November 17th Options Trading For Sage Therapeutics (SAGE)

Investors in Sage Therapeutics Inc saw new options become available this week, for the November 17th expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the...

SAGE : 83.15 (-1.38%)
Pershing Gold to Present at 2017 European Gold Forum

Pershing Gold Corporation (NASDAQ:PGLC) (TSX: PGLC) (FWB:7PG1) ("Pershing Gold" or the "Company"), the emerging Nevada gold producer advancing the Relief Canyon Mine, today announced that Stephen Alfers...

PGLC.TO : 3.78 (-0.53%)
SAGE : 83.15 (-1.38%)
PGLC : 2.96 (-1.66%)

Van Meerten Stock Picks

5 Mid Cap Picks
Today I wanted to find 5 Mid Cap Stocks with current momentum, so I used Barchart to sort the S&P 400 Mid Cap Index stocks first for the highest Weighted Alpha, then again for technical buy signal s of 80% or more.
CGNX -0.77 , IPGP -0.88 , NVR -1.18 , TTWO -0.48 , AAN -0.73
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

Barchart Morning Call

OVERNIGHT MARKETS AND NEWS Sep E-mini S&Ps ( ESU17 -0.16% ) this morning are down -0.13% and European stocks are down -0.29% as weakness in energy stocks drags the overall market lower. Sep WTI crude oil ( CLU17 -0.34% ) is down ... Read More

Chart of the Day

Chart of the Day

Health Insurance Innovations (HIIQ) is the Barchart Chart of the Day.  The health insurance company has a Trend Spotter buy signal, a Weighted Alpha of 341.00+ and gained 538.73% in the last year.
Read More

Brugler Ag Report

Today's Commentary

Corn futures are mostly a penny higher this morning ahead of the weekly USDA Export Sales report. They ended Wednesday with most contacts 1 1/2 to 2 3/4 lower. Preliminary open interest rose 4,637 contracts. The weekly EIA report indicated that a r...
Read More

Alan Brugler writes this daily agricultural markets overview with opening, midday and closing comments directed at the gain and meat Ag markets.

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.